Clinical Trial Update: A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS) [Phase 2]

View source ↗

Summary

Phase 2 study of oral decitabine/cedazuridine in combination with magrolimab for intermediate- to very high-risk myelodysplastic syndromes was terminated, with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Magrolimab (magrolimab)
• Oral Decitabine/Cedazuridine (decitabine/cedazuridine)

Snippet

Sponsor: Astex Pharmaceuticals, Inc. | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: TERMINATED | Results posted: 2024-10-02